Aurobindo Pharma climbs after USFDA nod for OTC drug

Shares of Aurobindo Pharma surged over 2 percent today after the firm got final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for treatment of osteoporosis.

Aurobindo Pharma gets USFDA nod for osteoporosis drug

Aurobindo Pharma gets USFDA nod for osteoporosis drug

Aurobindo Pharma has received final nod from the US health regulator to manufacture and market its generic Naproxen Sodium tablets used for the treatment of osteoporosis in postmenopausal wome

Aurobindo Pharma gets shareholders' nod to raise up to $600 million

Aurobindo Pharma on Thursday said it has received shareholders' nod to raise up to USD 600 million (around Rs 3,974 crore) via issue of securities.      

Aurobindo gets USFDA nod for multi disease treatment injection

Aurobindo gets USFDA nod for multi disease treatment injection

The company expects to launch the product by fourth quarter of the current fiscal.

Aurobindo gets USFDA nod to market generic Osteoporosis drug

Aurobindo gets USFDA nod to market generic Osteoporosis drug

 Aurobindo Pharma today said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.

Aurobindo Pharma to seek shareholders nod to raise $600 mn

Aurobindo Pharma will seek approval from its shareholders for an enabling resolution to raise up to USD 600 million (around Rs 3,974 crore) via issue of securities.

Aurobindo may launch Tramadol tablets in US market

Aurobindo may launch Tramadol tablets in US market

Aurobindo Pharma has rreceived final approval from the US Food and Drug Administration to launch Tramadol Hydrochloride extended-release tablets in the US maket.

Aurobindo to expand product basket; eyes $3bn revenues by FY18

The company has several levers to gain traction with a robust business model, a large differentiated product portfolio that addresses six key therapeutic areas and a growing presence in over 150 countries.

Aurobindo Pharma CEO Arvind Vasudeva resigns

Recently, the drug firm had said that it intends to invest up to Rs 900 crore this fiscal on various activities including capacity expansion, clinical trials and product filings.

Aurobindo gets USFDA nod to sell antibiotic oral suspension

The approval by the USFDA is for strengths of 100 mg/5 ml and 200 mg/5 ml and the product is ready for launch, Aurobindo Pharma said in a statement.

Aurobindo divests Australian arm to Eris Pharma

Aurobindo Pharma has divested stake in its Australian subsidiary to Eris Pharma for an undisclosed amount to focus on the US, European and emerging markets.

Plethico shares soar 20% on settlement pact with Aurobindo

Shares of Plethico Pharmaceuticals zoomed 20 percent Thursday after reaching settlement with Aurobindo Pharma related to the acquisition of US-based Natrol.

Aurobindo gets USFDA nod for Atracurium Besylate injections

Drug major Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Atracurium Besylate injections in the American market.

Plethico to pay Aurobindo Pharma $23.3 mn to settle dispute

Aurobindo Pharma on Thursday said Plethico will pay it USD 23.3 million to settle a dispute related to the acquisition of US-based Natrol.

CCEA clears Glenmark, Aurobindo proposals worth Rs 4,187 cr

Pharmaceutical majors Glenmark and Aurobindo's foreign investment proposals, worth Rs 4,187 crore, were approved by the government Tuesday.

Aurobindo gets tentative nod from USFDA for Lacosamide tablets

Drug firm Aurobindo Pharma has received tentative approval from the US health regulator USFDA for its generic Lacosamide tablets used in treatment of partial seizures in epilepsy patients.

Cos raise over $4-bn from QIP in FY15; $3-bn more in pipeline

Indian companies have raised over USD 4 billion (Rs 27,000 crore) from Qualified Institutional Placement (QIP) of shares so far in the current fiscal, while plans are underway to garner further funds worth an estimated USD 3 billion through this route.

Aurobindo Pharma to raise $350 million through QIP

Aurobindo Pharma Limited on Thursday said the company will raise up to USD 350 million by way of Qualified Institutions Placement (QIP).

Aurobindo, Lupin & Jubilant get USFDA nod for hypertension drug

Three domestic firms, Aurobindo Pharma, Lupin and Jubilant Life Sciences, have received final approval from US health regulator to sell generic copies of Valsartan tablets used for treatment of hypertension.

Constable, suspect in pharma tycoon kidnapping bid, nabbed

Police have picked up a constable of Andhra Pradesh Special Police (APSP), who had once worked with anti-Naxal Greyhounds force, in connection with yesterday's failed attempt to abduct vice-chairman of Aurobindo Pharma K Nityananda Reddy.